Connect Sign In
Diagnostic laboratory testing remains important for detecting active COVID-19 infection in vaccinated, partially vaccinated, and unvaccinated individuals.
Point-of-care antigen testing with the Abbott BinaxNOW COVID-19 Ag Card is not as sensitive as standard NAATs for detecting SARS-CoV-2 in asymptomatic college students, according to a study.
ARUP Laboratories announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious “United Kingdom (UK) variant” of the virus.
ARUP and University of Utah Health continue to research the safety and efficacy of COVID-19 convalescent plasma (CCP) in four multicenter randomized clinical trials.
Which types of innovation, adaptation, and acceleration happened in diagnostic technology companies in the face of the COVID-19 pandemic? Are the intensity and fast-moving strategies even sustainable?
A recording of an hour-long webinar updating the status of diagnostic testing for SARS-CoV-2 nearly a year after the first tests were introduced is now available to watch for free.
ARUP Laboratories has made a new resource available to laboratory leaders and others in healthcare to help explain how the first FDA-approved SARS-CoV-2 vaccines work.
ARUP announced the availability to clients nationwide of a combined test to detect and differentiate COVID-19, influenza, and respiratory syncytial virus (RSV).
ARUP Laboratories now offers testing to detect the virus that causes COVID-19 using saliva specimens. The molecular diagnostic test is available with preapproval to ARUP clients nationwide.
As a national EAP program to deliver COVID-19 convalescent plasma to hospitalized patients with COVID-19 concludes, researchers are transitioning to multicenter randomized clinical trials.
